Reference | Study Design | Exposure Group | Control Group | Measure | Memory Domain | Attention Domain | Executive Function Domain | General Cognitive Impairment (Domain- Nonspecific) |
Schmidt et al. [24] | Cross-sectional | Various Solid Malignancies CH+ (n = 3108) | n/a | QLACS | Patients reporting as abnormal: 65.4% | n/a
| n/a | Patient reporting as abnormal: 45.7% |
Schagen et al. [25] | Cross-sectional | BC CH+ (n = 39) | BC CH− (n = 34) | 5-point Likert scale | Patients reporting as abnormal: 31% (CH+) vs 6% (CH−) (p = 0.007) | Patients reporting as abnormal: 21% (CH+) vs 3% (CH−) (p = 0.022) | n/a | n/a |
Downie et al. [26] | Cross-sectional | BC CH+ (n = 21) | n/a | Semi-structured interview | Patients reporting as abnormal: %95 | Patients reporting as abnormal: 90% | Patients reporting as abnormal: 43% | n/a |
Shilling et al. [27] | Longitudinal | BC CH+ (n = 142) | n/a | Semi-structured interview | Patients reporting as abnormal: - 71% at 6 months post-treatment - 60% at 18 months post-treatment; | Patients reporting as abnormal: - 64% at 6 months post-treatment - 42% at 18 months post-treatment | n/a | n/a |
Skaali et al. [28] | Cross-sectional | TC CH+ one cycle of chemotherapy (n = 38); two or more cycles of chemotherapy (n = 53) | TC CH− (n = 31) | Semi-structured interview | Patients reporting as abnormal: - 26% (CH+) vs 7% (CH−) after one cycle of chemotherapy (p = 0.08); - 25% (CH+) vs 7% (CH−) after two or more cycles of chemotherapy (p = 0.08) | Patients reporting as abnormal: - 21% (CH+) vs 3% (CH−) after one cycle of chemotherapy (p = 0.09); - 13% (CH+) vs 3% (CH−) after two or more cycles of chemotherapy (p = 0.09) | n/a | Patients reporting as abnormal: - 29% (CH+) vs 10% (CH−) after one cycle of chemotherapy (p = 0.1); - 29% (CH+) vs 10% (CH−) after two or more cycles of chemotherapy (p = 0.1) |